Generic Name and Formulations:
Tafluprost 0.0015%; oph soln; preservative-free.
Indications for ZIOPTAN:
For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
1 drop in conjunctival sac of affected eye(s) once daily in the PM.
Do not exceed recommended dose (may reduce efficacy). Active intraocular inflammation (eg, iritis/uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Pregnancy (Cat.C); use effective contraception. Nursing mothers.
Allow at least 5 minutes between application of other topical oph agents.
Conjunctival hyperemia, ocular stinging/irritation, ocular pruritus including allergic conjunctivitis, cataract, dry eye, ocular pain, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), other eyelash changes, blurred vision, macular edema, headache, cold, cough, urinary tract infection.
Single-use containers (0.3mL)—30, 90
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|